KSE - Delayed Quote KRW

Ildong Pharmaceutical Co., Ltd. (249420.KS)

Compare
10,950.00 -440.00 (-3.86%)
At close: December 20 at 3:30:29 PM GMT+9
Loading Chart for 249420.KS
DELL
  • Previous Close 11,390.00
  • Open 11,400.00
  • Bid 10,980.00 x --
  • Ask 11,080.00 x --
  • Day's Range 10,950.00 - 11,450.00
  • 52 Week Range 10,560.00 - 20,500.00
  • Volume 95,236
  • Avg. Volume 86,822
  • Market Cap (intraday) 305.86B
  • Beta (5Y Monthly) 0.91
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date --
  • Forward Dividend & Yield --
  • Ex-Dividend Date Dec 27, 2019
  • 1y Target Est 25,000.00

Ildong Pharmaceutical Co., Ltd. develops, manufactures, and sells pharmaceutical products in South Korea. The company offers active lactic acid bacterial and anti-diarrheal agents, antibiotics, antifungal and antiviral products, anti-histamine drugs, antineoplastic agents, and NSAIDs and analgesics, as well as vitamins, minerals, and nutrients; and drugs for blood circulation, cardiovascular and central nervous system, dental, endocrine and metabolic system, gastrointestinal system, respiratory system, topical preparation, and urogenital system applications. It also provides raw material drugs; health foods and foods; cosmetics; medical devices for scar treatment; and other drugs for treating thick wounds, osteoarthritis, periarthritis of shoulder, and artificial tears, as well as feminine cleanser products. In addition, the company manages licenses and provides contract manufacturing services. It also exports its products to approximately 20 countries worldwide. Ildong Pharmaceutical Co., Ltd. a strategic collaboration with Evotec SE to accelerate the development of various Ildong's proprietary projects through access to Evotec's INDiGO platform. The company was founded in 1941 and is headquartered in Seoul, South Korea.

www.ildong.com

1,020

Full Time Employees

December 31

Fiscal Year Ends

Recent News: 249420.KS

View More

Performance Overview: 249420.KS

Trailing total returns as of 12/20/2024, which may include dividends or other distributions. Benchmark is

.

YTD Return

249420.KS
39.70%
KOSPI Composite Index
9.46%

1-Year Return

249420.KS
33.03%
KOSPI Composite Index
8.04%

3-Year Return

249420.KS
70.80%
KOSPI Composite Index
18.86%

5-Year Return

249420.KS
31.15%
KOSPI Composite Index
9.07%

Compare To: 249420.KS

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Statistics: 249420.KS

View More

Valuation Measures

Annual
As of 12/20/2024
  • Market Cap

    305.86B

  • Enterprise Value

    439.32B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    0.50

  • Price/Book (mrq)

    1.95

  • Enterprise Value/Revenue

    0.72

  • Enterprise Value/EBITDA

    17.95

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    -8.06%

  • Return on Assets (ttm)

    -1.92%

  • Return on Equity (ttm)

    -30.55%

  • Revenue (ttm)

    603.86B

  • Net Income Avi to Common (ttm)

    -48.68B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    70.91B

  • Total Debt/Equity (mrq)

    126.49%

  • Levered Free Cash Flow (ttm)

    12.96B

Research Analysis: 249420.KS

View More

Company Insights: 249420.KS

Research Reports: 249420.KS

View More

People Also Watch